SMAD4 and renal cell carcinoma: Our findings, for the first time, propose that targeting SMAD4 as a pivotal transducer of the TGF-β-signaling pathway may be effective as a supplementary targeted therapy against renal CSCs and may improve the RCC prognosis, particularly the ccRCC subtype.